Fig. 2From: A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitusKaplan–Meier plot of time to first major adverse cardiac event in the intention-to-treat populationBack to article page